Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma

NCT00450138 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00450138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00450138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2006
Completion date
November 30, 2011
Enrollment
48 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer